Pantec Biosolutions appoints new Board members
New appointments are set to enhance future business and finance strategies
Pantec Biosolutions AG, a privately-owned company developing technologies for transdermal drug delivery, announced the appointment of Burkhard Feurstein and Michael Armbruester to the Board following their election at the annual shareholders meeting held on April 24, 2008.
Mr Feurstein is Director of Finance at Gamma Capital Partners AG (GCP), a venture capital investment company. He has over 20 years expertise in investment and project finance, including a decade of direct and fund investment experience. Prior to GCP, Mr Feurstein was Managing Director of Vienna-based venture capitalists, Invest Equity, specialising in early stage technology companies. In 1990, he initiated and implemented the government-sponsored capital guarantee scheme (AWS), helping to kick-start the Austrian venture capital industry. His core expertise lies in finance and turn-around management with operative experience as an industrial manager in the biopharmaceuticals and medical technology industries. Mr Feurstein has a M.S. degree in theoretical physics from Vienna Technical University.
Michael Armbruester graduated from the University of Evansville in the U.S. with a Bachelor of Science degree in international business in 1986. Post graduation, he worked for one of the world's largest Swiss based commodity houses. After his initial training, Mr Armbruester rose to become a senior trader, with postings in Australia, Hong Kong, Switzerland and the United States, a senior partner and was made head of the Company's aluminium operations for both North and South America. He was also extensively involved in the acquisition of three aluminium manufacturing facilities and served as President for each. At their peak, these companies employed in excess of 2500 staff. Mr Armbruester has held numerous Board positions, developing a network of contacts in the venture capital and hedge fund sectors. He formed JB Commodities in early 2005. In just three years, the Company, which specialises in physical commodity trading and financial futures, has established four offices in four countries and is headquartered in Switzerland.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
